Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ10667MR)

This product GTTS-WQ10667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001145645.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	10673
UniProt ID	Q9Y275

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10667MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3287MR	IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ASN-1
GTTS-WQ8904MR	IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	IGE25
GTTS-WQ7097MR	IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	FE 999301
GTTS-WQ5996MR	IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	CNTO 095
GTTS-WQ13342MR	IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	PF-06801591
GTTS-WQ6774MR	IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	DS-1062
GTTS-WQ9130MR	IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	IMGN242
GTTS-WQ5721MR	IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	CEA TCB

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST